Research on discovering and developing new drugs. Covers structure-revealing tools, eye-disease mechanisms, protein screening, and once-daily oral medicines.
The ISSCR Consortium brings together industry, academia, and regulatory experts to establish standards and develop tools for stem cell-based models. Takeda's membership aims to accelerate the adoption of human stem cell-derived models in drug discovery and development.
Researchers at the University of São Paulo have identified IP6K as a potential target for treating Chagas disease. The study found that reducing IP6K expression impairs the Trypanosoma cruzi parasite's ability to differentiate and maintain its infection cycle in human heart cells. Further studies are needed to understand the role of IP...
Researchers developed a new cancer therapeutic strategy that targets two proteins to improve efficacy and reduce side effects in prostate cancer. The approach demonstrated greater antitumor activity while sparing normal cells, offering a potential more effective treatment strategy.
Researchers at the University of Cincinnati found a potential biomarker for PTSD susceptibility in female animal models, suggesting a link to stress hormone patterns. The study suggests that a simple stress provocation test could serve as a clinical biomarker for PTSD risk and point toward early interventions. The findings raise the po...
Researchers use AI to screen existing compounds for therapeutic potential, identifying novel compounds that bind to specific receptors. The framework, known as Full-Spectrum Generative Lead Discovery (FSGLD), uses generative AI to uncover patterns in molecular fingerprints that point to useful properties.
The Phase 2 trial will evaluate the efficacy and safety of OYE-101 in adult surgical patients, aiming to accelerate emergence from general anesthesia and improve postoperative recovery. The trial is expected to enroll approximately 40 patients and will assess time to emergence, sedation, and alertness, as well as postoperative recovery...
The UVA Biotech Innovation Fund will support the SPARK Innovative Medicines program, helping to accelerate promising discoveries into new treatments and cures. The fund will provide long-term support for researchers to overcome the critical gap between discovery and clinical application.
Researchers developed FIND, a drug discovery platform that uses DNA nanoswitches to select drug candidates based on their effects on protein-protein interactions. The platform identifies molecules that modulate binding interactions between two proteins, introducing unprecedented functionality and efficiency into drug screening.
Researchers map the capabilities of new approach methodologies to replace animal testing, with organoids and organ-on-a-chip systems showing promising results, but acknowledging limitations and need for further development and validation
The 'Anyone Can Dock' tool automates molecular docking preparation and provides interactive visualization and analysis for researchers to explore protein-ligand interactions. It supports batch docking and AI-assisted interpretation, making it more accessible for research, education, and scientific exploration.
Researchers found that sotagliflozin reduces excessive platelet activation, a process that can lead to dangerous blood clots that block flow to the heart and brain. The drug also makes platelets less likely to stick together and form blood clots, potentially lowering the risk of heart attack and stroke.
A University of Oklahoma researcher is using a $1.9 million NIH award to study how the body moves drugs into the liver and how other medications can disrupt that process. The goal is to develop a strategy that better predicts transporter-related drug interactions before patients are harmed.
A novel antibody therapy empowers the immune system's tumor-fighting capabilities by targeting immune-suppressing T cells with greater precision. The therapy, which combines targeting CCR8 and activating CD3, promotes antitumor immunity in mice and nonhuman primates.
Researchers capture radical positions and motion on 100-picosecond timescale using time-resolved X-rays, revealing radical behavior varies by neighboring molecule. The findings provide new insights into reaction selectivity and could lead to more precise production of effective new drugs and high-performance materials.
Researchers at RIKEN have developed a synthetic compound that uses excess carbon monoxide produced by cancer cells to trigger the production of anti-cancer drugs within the cells themselves. The compound selectively targets tumors and avoids harming healthy cells, offering a promising new approach to cancer treatment.
Researchers propose using aging rate indicators to detect interventions that slow aging pace. The study aims to accelerate anti-aging breakthroughs, but regulatory barriers and equitable access are discussed.
The ISSCR symposium in Kyoto, Japan celebrates 20 years of iPSC discovery, exploring fundamental discoveries, clinical translation, and emerging stem cell therapies. The event highlights key findings from recent research, including advances in iPSC biology, genetic stability, and disease modeling.
Melanie Ott and Alex Marson, directors at Gladstone Institutes, have been elected to the National Academy of Medicine for their pioneering achievements in science and medicine. Their work focuses on understanding viral mechanisms, developing innovative treatments, and repurposing human immune cells to fight disease.
Researchers at Korea University developed an AI-guided strategy to discover potential antiviral compounds against viruses like HIV-1 and SARS-CoV-2. The study combined AI-guided molecular design with experimental validation to identify potential inhibitors of a host enzyme involved in viral replication.
KAIST researchers developed an unmanned synthesis platform combining robots and light to automate the entire process from mixing raw materials to synthesis and analysis. The platform successfully synthesized the N-methyl pyrrole scaffold and demonstrated potential for continuous manufacturing.
DS1025, a CD25-directed antibody drug conjugate, targets immunosuppressive regulatory T cells in the tumor microenvironment, aiming to reduce a mechanism that can limit the body's immune response against cancer. The trial is an international effort to investigate DS1025 in patients with advanced solid tumors.
Researchers at Aston University have engineered vegan honey alternatives with antimicrobial properties similar to mānuka honey, a natural product known for its antibacterial activity. The vegan honey formulations were tested against a culture of a highly drug-resistant bacterium, with promising results.
Juvmo, a Parkinson's disease drug, has been approved by the FDA and offers a new treatment option for patients, potentially reducing side effects. The drug's unique mechanism of action provides relief from motor symptoms, and its approval marks a significant milestone in the research of UVA Health scientists.
Personalized medicines can improve dose accuracy and accessibility for patients with unique treatment needs, such as children and older adults with changing medication requirements. A new technology, inspired by 3D printing, enables mass production of customized treatments, increasing product quality and consistency.
Researchers found that the cancer drug zavondemstat and a closely related compound QC6352 do not primarily target KDM4, but instead work by blocking DHODH, an enzyme cancer cells rely on to produce molecules needed for rapid growth. This discovery highlights a broader challenge in cancer drug development, emphasizing the need for great...
Researchers at Juntendo University discovered a lipid signaling pathway involving 12-HHT and BLT2 that promotes plasma membrane repair and protects cells from membrane-damaging insults. Cells with enhanced BLT2 signaling showed better survival rates, less membrane leakage, and improved mitochondrial health after toxin exposure.
Researchers discovered gallic acid suppresses tumor progression by targeting the NF-κB/KLF7/L1CAM axis in prostate cancer. The study demonstrated that gallic acid significantly impaired aggressive behaviors of PC-3 and LNCaP cells without toxicity to normal cells.
Professor John Bower joins the University of Bath as the new Raymond Schinazi and Family Chair of Science, bringing expertise in synthetic and medicinal chemistry to enhance the university's research capabilities. He aims to translate fundamental research into real-world impact, supporting the development of new sustainable processes f...
A phase Ib/II trial evaluated the triple combination of famitinib, dalpiciclib, and fulvestrant in HR+/HER2− breast cancer, meeting initial efficacy targets with a confirmed objective response rate of 51.9%. However, the regimen showed no superiority over standard first-line treatments and was terminated early due to safety concerns.
The University of Kansas has received $5.8 million in NIH funding to further its Chemical Biology of Infectious Disease center, which aims to develop targeted treatments for antibiotic-resistant pathogens. The center's collaborative approach will focus on protecting the beneficial microbiome while defeating resistance mechanisms.
A UCF researcher and her team used AI to screen existing FDA-approved drugs for potential treatments of schwannoma tumors in children with Neurofibromatosis type 2. The research identified 10 promising candidates, with the most favorable targets stopping tumor cell growth by impacting different cellular mechanisms.
A new drug, Kamuvudine K-9, has been shown to preserve nerve fibers and halt neurological damage in a mouse model of multiple sclerosis. The drug, derived from HIV drugs, has been found to be more effective than existing treatments in restoring function and reducing inflammation.
New York University researchers have trained an AI model to predict stable tautomers in drug-like molecules, addressing a challenge in molecular design. The model, released as an open-source tool, can analyze large molecular libraries and identify correct tautomer assignments.
The University of Melbourne has joined the Structural Genomics Consortium to develop AI-powered tools for drug discovery, targeting rare diseases. The new SGC-Melbourne facility will generate large-scale datasets on protein-molecule interactions, enabling the creation of high-quality data needed for AI to predict new molecular tools.
A virtual biotech company powered by AI agents has made groundbreaking discoveries in drug discovery, including a biological signal that predicts which drug candidates are more likely to succeed. The company has also designed a cancer therapy that was later independently built by a major pharmaceutical company.
A new treatment option has been approved in Japan for patients with PFIC types 1 and 2, a rare genetic liver disorder. The treatment, which targets the mechanism behind bile movement, may help slow down liver damage and improve quality of life for children and adults with these disorders.
The conference will explore next-generation biologics and immunotherapies, targeted protein modulation, and emerging therapies for oncogenic drivers. Experts will discuss the role of artificial intelligence in accelerating therapeutic development.
Researchers identified a novel glycosyltransferase enzyme, PamUGT, from American pokeweed, which can decorate five major classes of natural products. The enzyme shows remarkable promiscuity, using multiple UDP-sugars to glycosylate diverse substrates.
Researchers discovered PECAM-dependent mechanism for immune cell traffic in the retina, identifying neutrophils as proresolving mediators. Targeting PECAM controlled white blood cell traffic, leading to improved clinical outcomes in uveitis model.
Researchers developed a flexible metal–organic framework, APF-40, to analyze large pharmaceutical molecules with complex structures. The framework enables the determination of structures from microgram-scale samples, aiding drug discovery and natural products research.
A new high-throughput tool developed by Stanford University scientists can detect small changes in protein levels within cells, enabling faster and more efficient drug discovery. By amplifying these changes, researchers can identify potential therapeutic targets for diseases like cancer, potentially leading to breakthroughs in treatment.
A clinical trial found that AZD5462, a new oral medication, was well-tolerated and improved cardiac remodeling and blood flow in patients with heart failure. The results suggest that AZD5462 may be a promising treatment option for patients with chronic heart failure.
The 21st Century Cures Act led to a significant decrease in the number of studies relied on for FDA approvals, from 3.41 to 1.39, between 2016 and 2024. This shift has raised concerns about the safety and effectiveness of new therapeutics.
A research team created an ultrathin artificial lung that reproduces the movement of alveoli, air sacs inside the lung, and demonstrates the response to influenza virus. The lung operated stably through 240,000 breaths and showed promise for studying lung disease and drug responses.
Researchers at Purdue University have developed L-32, a quinolone-based inhibitor that targets PTPN22, a negative regulator of the immune system. This compound promotes robust antitumor immunity and has improved potency, selectivity, and cellular efficacy compared to previous derivatives.
Researchers developed a first-in-class therapy targeting MYC, a protein involved in 70% of cancers, by disrupting its relationship with GSPT1. This approach showed strong anti-cancer activity in multiple types of blood cancers, including treatment-resistant models.
Surzen Biotherapeutics aims to develop effective pain relief without severe side effects by targeting opioid receptor pathways differently. The company plans to use peptides to block dimerization, reducing tolerance and improving efficacy.
Researchers at UH College of Pharmacy are developing breakthroughs to combat sepsis, a leading cause of hospital deaths, and diseases such as Alzheimer's and sickle cell disease. A dual-action nanomedicine has shown a 100% survival rate in preclinical trials for sepsis treatment.
Researchers found that dexamethasone reduces infection-driven macrophage metabolic activity and lowers inflammatory signals, preserving the immune system's ability to control the infection. This study suggests a new approach for managing nontuberculous mycobacterial disease.
The new integrations provide enterprise AI agents direct access to live, structured research data from Dimensions' 430M+ interconnected records. This allows for AI-assisted analytics across one of the world's most comprehensive linked views of global research activity.
Researchers have uncovered a key mechanism explaining how allergic inflammation in the skin can progress to a body-wide allergic response. IL-13 acts on dendritic cells, enhancing their ability to present allergens and promoting immune responses that produce antibodies.
Researchers have found a new compound that promotes joint health and reduces inflammation-related genes in a model of osteoarthritis. The drug, M04, has shown promise as an innovative OA therapy by slowing down the disease process, giving people more years of pain-free living.
Tirzepatide has been shown to reduce the risk of heart attacks and hospitalizations due to infections in people with type 2 diabetes and obesity. The study found a relative risk reduction of about one-third, corresponding to a 36% reduced risk of infection-related hospitalization.
Researchers created nearly 700 new cancer models derived from patient tumors to aid in drug development. The models, representing 25 types of cancer, are now available for global use, providing a resource for identifying new drug targets and testing potential treatments.
Researchers at the University of Manchester have developed a new family of antifungal agents that are more potent and less toxic than existing treatments. The compounds, which were discovered through genome mining, showed increased antifungal activity and improved solubility compared to existing drugs.
A new study reveals that photoreceptors possess an internal recycling system that removes damaged proteins and maintains cellular health. This discovery has important implications for inherited retinal diseases and raises questions about the safety of certain drugs in clinical testing.
Revolver Therapeutics, a spin-out company from the University of Bath, has won the Health category of the Royal Society of Chemistry's Emerging Technologies Competition with its proprietary discovery platform. The platform generates and tests millions of constrained peptide drug candidates directly inside living cells, selecting for mo...
A new peptide derived from cone snail venom has been shown to significantly reduce inflammation-induced pain in an animal model. The peptide specifically inhibits the noradrenaline transporter, supporting the body's own pain-inhibiting mechanisms.
Researchers have identified a widespread source of error in a popular genome study method and created a machine-learning tool to correct it. PATTY uses machine learning to reduce artifacts while preserving real signals in noisy data, giving researchers a clearer view of gene activity control.
Researchers at Texas A&M University have found a way to intervene early in traumatic brain injuries using a natural, gut-derived chemical that prevents post-traumatic epilepsy from taking root. The treatment reduced brain inflammation, improved memory and mood, protected brain cells, made seizures both rarer and harder to trigger.